Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07493460 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

Study acronym: WU 445
StatusActive, Not Recruiting
PhasePhase 4
Started2025-08-26
View on ClinicalTrials.gov ↗
This study is being done to understand and measure how the immune system responds to and remembers different types of vaccines. To do this, four vaccines approved by the U.S. Food and Drug Administration (FDA) will be given simultaneously to participants. Participants will be volumteers who are healthy adults (18 years old or older) and willing to receive the yearly trivalent inactivated influenza vaccine (TIV), the tetanus, diphtheria, and acellular pertussis vaccine (Tdap), the nonvalent HPV (HPV) vaccine, hepatitis A virus (HAV) vaccine and undergo study procedures. Procedures will include: * medical history relevant to the study, including medications and vaccines received. * Vitals (blood pressure, pulse) and temperature * Height and weight. * Physical exams. * Receive the TIV, Tdap, HPV, and HAV vaccines. * Blood samples collected for immunologic tests and genetic analysis. * Donate bone marrow by needle aspiration at a maximum of seven visits. * Complete memory aid every evening for 7 days after vaccination Optional Procedures include: * Donate bone marrow core biopsies at the same visits * Ultrasound of lymph nodes and fine needle aspirates of lymph nodes in both arm pits at a maximum of eight separate visits There will be a screening visit and and a Day 1 where vaccinations will occur and subsequent visits at Day 8, Day 14, Day 29, Day 57, Day 121, Day 181, Day 366, Day 546, and Day 731. At each of these visits health status, vital signs and blood collection will occur. A bone marrow aspirate and lymph node aspirate will be collected at screening. The six additional bone marrow aspirates will be repeated at D29, D91, D181, D366, D546, and D731. The optional bone marrow core biopsy will also be repeated at that time. Up to seven separate visits will be scheduled for the follow-up lymph node aspirates (D29, D57, D91, D181, D366, D546, and D731) Study participation will be 24 months.

Amendment history 2 changes detected by DataLookout

2026-07-02
notable
Primary completion pushed: 2026-08 → 2026-10
2026-04-23
notable
Trial status changed: Recruiting → Active, Not Recruiting
Trial Details
NCT Number NCT07493460
Lead Sponsor Washington University School of Medicine
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Immunology, Healthy Adults
Enrollment 25 participants
Start Date 2025-08-26
Primary Completion 2026-10 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-01